Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)

• Status: Completed
• Trial end date: 2001-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active comparator.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Loratadine; Montelukast

Criteria

Inclusion Criteria:

• Patient has a documented history of season allergic rhinitis symptoms that flare up during the study season

• Patient is a nonsmoker

• Patient is in good general health

Exclusion Criteria:

• Patient is hospitalized

• Patient is a woman who is <8 weeks postpartum or is breast-feeding

• Patient has had major surgery in the past 4 weeks

• Patient intends to move or vacation away during the study

• Patient is a current or past abuser of alcohol or illicit drugs